Effect of selenium supplementation on lipid profile in hemodialysis patients.
BACKGROUND
One of the major causes of mortality in chronic kidney disease (CKD) patients on hemodialysis is premature atherosclerosis. Selenium, a trace element involved in important enzymatic activities inside the body, has protective effects against lipid oxidation and inhibits cholesterol accumulation in blood vessels.


OBJECTIVE
To determine the effect of selenium supplementation on lipid profile in hemodialysis patients.


METHODS
In this double-blinded randomized clinical trial which lasted for 3 months, 84 hemodialysis patients with selenium deficiency were divided into experimental group (received selenium supplementation) or control group (received placebo). Total cholesterol, low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), blood urea nitrogen (BUN), creatinine, and selenium level were measured before and after the study.


RESULTS
Mean (±SD) serum LDL-C level significantly increased in experimental group from 85.66 (±31.12) to 109.12 (±32.29) mg/dl (P<0.001). Likewise, in control group serum LDL-C significantly increased from 80.55 (±21.13) to 97.05 (±28.07) mg/dl (P<0.001). However, with control of LDL-C effect before and after the study, it was revealed that LDL-C change was not statistically significant (P=0.21). Similarly, total cholesterol and triglyceride levels did not show significant changes before and after the study in any group.


CONCLUSIONS
Selenium supplementation had no beneficial effect on lipid profile in hemodialysis patients.
Nephrology and Urology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Hamidreza
H
Omrani
Nephrology and Urology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Sima
S
Golmohamadi
Department of Nutrition, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Yahya
Y
Pasdar
Department of Internal Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Kambiz
K
Jasemi
Department of Biostatistics and Epidemiology, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Afshin
A
Almasi
Chronic kidney disease; End stage renal disease; Hemodialysis; Lipid; Selenium
Nephrol Dial Transplant. 2011 Apr;26(4):1367-74
20713977
J Anim Sci. 1990 May;68(5):1311-7
2365642
Kidney Int. 2002 Dec;62(6):2238-45
12427151
Biol Trace Elem Res. 2011 Dec;144(1-3):496-503
21789541
Nephrol Dial Transplant. 2011 Oct;26(10):3331-8
21372251
Kidney Int. 2008 Feb;73(4):391-8
18094682
Am J Kidney Dis. 2004 Nov;44(5 Suppl 2):39-46
15486873
J Trace Elem Med Biol. 2010 Jan;24(1):27-30
20122576
Dis Colon Rectum. 1998 Mar;41(3):328-35
9514428
Semin Nephrol. 2009 Jan;29(1):39-49
19121473
Nephrol Dial Transplant. 2002;17 Suppl 11:28-31
12386254
Am J Kidney Dis. 2003 Nov;42(5):864-81
14582032
Biol Trace Elem Res. 2009 Oct;131(1):1-12
19266172
Biol Trace Elem Res. 2010 Dec;137(3):335-9
20039146
Nutr Cancer. 1997;28(2):125-9
9290116
Wien Klin Wochenschr. 1997 Jan 17;109(1):13-9
9037743